# Dose-escalation Study of Oral CX-4945

> **NCT00891280** · PHASE1 · UNKNOWN · sponsor: **Cylene Pharmaceuticals** · enrollment: 55 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Breast Cancer
- Inflammatory Breast Cancer
- Castleman's Disease
- Multiple Myeloma

## Interventions

- **DRUG:** CX-4945 oral formulation

## Key facts

- **NCT ID:** NCT00891280
- **Lead sponsor:** Cylene Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-02
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2011-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891280, "Dose-escalation Study of Oral CX-4945". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00891280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*